Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Anal HSIL confirmed by biopsy no more than 30 days prior to entry~* Anal HSIL deemed not amenable to therapy or participant declines routine ablative therapy~* HIV positive~* Stable HIV treatment regimen for at least 8 weeks prior to entry~* At least 18 years of age~* Women of childbearing potential must use contraception~* Platelet count above 70,000/mm3 within 30 days prior to entry~* ANC greater or equal to 1000/mm3 within 30 days prior to entry~* Creatinine less then or equal to 1.5 times ULN within 30 days prior to entry~* AST and ALT less than or equal to 3 times ULN within 30 days prior to entry~Exclusion Criteria:~* Prior history of invasive anal, cervical, vaginal, or vulvar cancer~* Pregnancy or lactation and breast-feeding~* Must not participate in a conception process including sperm donation~* Medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with ability to comply with protocol~* Known allergy to any topical cream components~* Patients with lesions clinically suspicious per HRA examiner for early progression (less than one year) to anal cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).